Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Published:2018-02-14 Issue: Volume: Page:
ISSN:
Container-title:General Session Abstracts
language:
Short-container-title:

Author:

Tripathy D,Sohn J,Im S-A,Colleoni M,Franke F,Bardia A,Harbeck N,Hurvitz S,Chow L,Lee KS,Campos-Gomez S,Villanueva Vazquez R,Jung KH,Carlson G,Hughes G,Diaz-Padilla I,Germa C,Hirawat S,Lu Y-S

Publisher

American Association for Cancer Research

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy;Frontiers in Pharmacology;2023-02-03

2. Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases;Meditsinskiy sovet = Medical Council;2022-12-06

3. The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?;Cancers;2022-05-30

4. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer;Cancer Management and Research;2021-11

5. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Annals of Oncology;2020-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP